# Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19

> **NCT04701502** · PHASE2 · COMPLETED · sponsor: **Catalysis SL** · enrollment: 60 (actual)

## Conditions studied

- Covid19
- Respiratory Disease
- Immune System
- Immunomodulator
- Antiseptic
- Supportive Care

## Interventions

- **DIETARY_SUPPLEMENT:** Viusid
- **DIETARY_SUPPLEMENT:** Asbrip
- **DRUG:** Standard Care

## Key facts

- **NCT ID:** NCT04701502
- **Lead sponsor:** Catalysis SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-09
- **Primary completion:** 2021-02-15
- **Final completion:** 2021-02-15
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04701502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04701502, "Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04701502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*